Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) rose 2.9% during trading on Thursday . The company traded as high as $1.81 and last traded at $1.80. Approximately 34,888 shares traded hands during trading, a decline of 38% from the average daily volume of 56,428 shares. The stock had previously closed at $1.75.
Plus Therapeutics Stock Up 2.9 %
The stock has a market cap of $10.26 million, a PE ratio of -0.59 and a beta of 0.54. The business’s fifty day moving average is $1.92 and its 200 day moving average is $1.92.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.34. The firm had revenue of $1.68 million for the quarter. Plus Therapeutics had a negative net margin of 193.49% and a negative return on equity of 805.57%. During the same period in the prior year, the firm posted ($2.10) EPS.
Insiders Place Their Bets
Plus Therapeutics Company Profile
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Further Reading
- Five stocks we like better than Plus Therapeutics
- How to Capture the Benefits of Dividend Increases
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Canadian Penny Stocks: Can They Make You Rich?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What is Short Interest? How to Use It
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.